Page 1

Exhibit 99.1 Axonics® Reports Second Quarter 2021 Financial Results Total revenue of $ 45.9 million in 2Q21 , including record SNM revenue of $ 40.2 million BulkamidⓇ revenue of $ 5.7 million in first full quarter since acquisition Fiscal year 2021 revenue guidance increased to a range of $ 186 million to $ 188 million - IRVINE , Calif - August 5 , 2021 Axonics , Inc. ( Nasdaq : AXNX ) , a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction , today reported financial results for the second quarter ended June 30 , 2021 . " This quarter's record revenue result reflects the growing demand for our best - in - class incontinence solutions , " said Raymond W. Cohen , chief executive officer of Axonics . “ Clinical outcomes and satisfaction with our rechargeable sacral neuromodulation ( SNM ) system remain high , with over 12,000 patients having been implanted since our U.S. commercial launch in late 2019. Given the strong commercial momentum for both SNM and Bulkamid , we have increased our fiscal year 2021 revenue guidance to be in the range of $ 186 million to $ 188 million . " Cohen continued , “ During the second quarter , we trained our entire U.S. field team on Bulkamid and are now executing a broad rollout to physicians across the United States . Physician enthusiasm to incorporate this next - generation bulking agent into their practices to treat female stress urinary incontinence is significant as evidenced by our second quarter results and the six fully booked regional seminars we are hosting this summer to provide Bulkamid wet - lab training . In late June , we filed a PMA supplement with the FDA for our new long - lived , non- rechargeable implantable neurostimulator . We anticipate the 10 - year life and fully recharge - free system will be a very attractive proposition for patients and physicians . The progress on these key initiatives and the continued expansion of our U.S. commercial team gives us confidence in achieving our ambitious long - term growth objectives . ” Second Quarter 2021 Financial Results Net revenue was $ 45.9 million in the second quarter 2021 , an increase of 202 % compared to $ 15.2 million in the prior year period . ° Sacral neuromodulation revenue was $ 40.2 million , of which $ 39.2 million was generated in the U.S. and the remainder in select international markets . • ° Bulkamid revenue was $ 5.7 million , of which $ 2.4 million was generated in the U.S. and the remainder in international markets . Gross margin was 62.6 % in the second quarter 2021 compared to 44.4 % in the prior year period . • Operating expenses were $ 44.7 million in the second quarter 2021 compared to $ 26.2 million in the prior year period . • Net loss was $ 25.1 million in the second quarter 2021 compared to a net loss of $ 19.8 million in the prior year period . • As of June 30 , 2021 , cash and cash equivalents were $ 231.1 million . In mid - June , Axonics prepaid and terminated its $ 75 million term loan with Silicon Valley Bank .